Netupitant
ATC — · 9 markets · 12 records
AU 3 records · 2 strengths
- 300 mgcapsuleAKYNZEOAKYNZEO netupitant/palonosetron (as hydrochloride) 300 mg/500 mcg capsule blister pack
Records without a stated strength · 1 AKYNZEO
US 1 records · 1 strengths
- 300 mgcapsuleAKYNZEO
GB 1 records · 1 strengths
- 300 mgcapsuleAKYNZEO
CA 1 records · 1 strengths
- 300 mgcapsuleAKYNZEO
SG 1 records · 1 strengths
- 300 mgcapsuleAKYNZEO
ES 1 records · 1 strengths
- 300 mgcapsuleAKYNZEO
TW 1 records · 1 strengths
Records without a stated strength · 1 AKYNZEO、嘔可舒膠囊
HK 1 records · 1 strengths
Records without a stated strength · 1 AKYNZEO
| Strength / form / release | US | GB | CA | AU | SG | ES | TW | HK |
|---|---|---|---|---|---|---|---|---|
| 300 mg capsule | AKYNZEO | AKYNZEO | AKYNZEO | AKYNZEO AKYNZEO netupitant/palonosetron (as hydrochloride) 300 mg/500 mcg capsule blister pack | AKYNZEO | AKYNZEO | ||
capsule | AKYNZEO 嘔可舒膠囊 | |||||||
unknown | AKYNZEO | AKYNZEO |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.